GLP-1 ( DrugBank: - )


1 disease
告示番号疾患名(ページ内リンク)臨床試験数
299嚢胞性線維症3

299. 嚢胞性線維症


臨床試験数 : 1,695 薬物数 : 1,527 - (DrugBank : 268) / 標的遺伝子数 : 111 - 標的パスウェイ数 : 174
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT04731272
(ClinicalTrials.gov)
April 20, 202126/1/2021GLP-1 Agonist Therapy in Cystic Fibrosis-Related Glucose IntoleranceEffect of GLP-1 Agonist Therapy on Insulin Secretion in Adults With Pancreatic Insufficient Cystic Fibrosis and Abnormal Glucose Tolerance: a Randomized, Open-label, Cross-over TrialCystic Fibrosis;Pancreatic Insufficiency;Abnormal Glucose Tolerance;DiabetesDrug: Dulaglutide 0.75Mg/0.5Ml Inj PenUniversity of PennsylvaniaChildren's Hospital of PhiladelphiaRecruiting18 YearsN/AAll30Phase 2United States
2NCT01975259
(ClinicalTrials.gov)
December 201311/9/2013Investigating the Incretin Effect in Cystic FibrosisInvestigating the Incretin Effect in Cystic FibrosisCystic FibrosisDrug: Oral Glucose Tolerance test (75g 2-hour);Drug: Modified Oral Glucose Tolerance Test (50g 4-hours);Drug: Matched isoglycemic clamp;Drug: Hyperglycemic clamp with concurrent GLP-1 infusion;Drug: Hyperglycemic Clamp with concurrent GIP infusion;Drug: Hyperglycemic clamp with placebo infusion;Other: Liquid Meal Test (Carbohydrate-rich);Other: Liquid Meal Test (Fat-rich);Other: Liquid Meal Test (Mixed);Device: Continuous Glucose MonitoringLiverpool Heart and Chest Hospital NHS Foundation TrustNULLCompleted17 Years50 YearsBoth50N/AUnited Kingdom
3NCT01851694
(ClinicalTrials.gov)
May 20138/5/2013Beta-cell Response to Incretin Hormones in Cystic FibrosisDetermination of Beta-cell Responsiveness to the Incretin Hormones GLP-1 and GIP in Cystic FibrosisCystic Fibrosis;Pancreatic InsufficiencyDrug: GLP-1;Drug: GIPUniversity of PennsylvaniaChildren's Hospital of PhiladelphiaRecruiting18 YearsN/AAll45N/AUnited States